Revon Media
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us
No Result
View All Result
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us
No Result
View All Result
Revon Media
No Result
View All Result

Duopharma Biotech reports higher 4Q 2021 revenue

A blockchain advantage
Share on FacebookShare on Twitter

Despite higher costs, Duopharma Biotech Berhad (Duopharma Biotech) saw its revenue in the fourth quarter of 2021, rising by 8.5 per cent to RM145.44 million.

In the quarter, profit after tax was RM15.72 million, resulting in earnings per share of 1.67 sen.

For the full year, net profit rose 12.07 per cent to RM65.68 million, while revenue increased 12.16 per cent to RM639.18 million.

Duopharma Biotech has declared a second interim dividend of 1.8 sen per share for the fiscal year ending Dec 31, 2021 (2020: second interim dividend of six sen per share) and resolved that the company’s Dividend Reinvestment Plan will apply to the second interim dividend.

Leonard Ariff Abdul Shatar, Group Managing Director, Duopharma Biotech

Compared to the previous year, the second interim dividend was reduced to free up more cash for existing business expansion and working capital purposes as part of the company’s de-gearing strategy.

According to Duopharma Biotech Group Managing Director Leonard Ariff Abdul Shatar, several developments will boost the company’s earnings in the coming quarters. This includes a RM375 million tender accepted by the Government to supply Insugen-Insulin Recombinant Human Formulations to the Ministry of Health (MoH) for three years through December 2024.

In addition, the contract to supply pharmaceutical and non-pharmaceutical products to government hospitals and clinics has been extended for 12 months until the end of end-2022.

Following the announcement in Budget 2022 and the gazette of the Finance Act 2021 that the period for additional reinvestment allowance will be extended to the year of assessment 2024, the company could save more than RM10 million upon the completion of some qualifying assets by 2024.

“Despite the operational and cost challenges, we are confident of the company’s long-term prospects as we believe the demand for healthcare and pharmaceutical products will continue to grow. This is evident in the Government’s increased allocation for the healthcare sector in Budget 2022,” Leonard Ariff said.

Tags: BusinessDuopharmaDuopharma BiotechLocal NewsPharmaceuticalThe Health 2022The Health Mar/AprtheHealth
Previous Post

Yayasan Sultan Ibrahim Johor donates medical equipment worth over RM28 mil

Next Post

Malaysian team develops new tool relating to breast cancer patients

Live Edition Paper

JUNE 2023 ePaper

MAY 2023 ePaper

 

Subscribe for free complimentary live editions:

Recent News

  • Burnout in academia
    September 3, 2021
    The physiological effects of contagion and isolation go beyond fear of […]
  • Handbook on youth mental health launched
    February 7, 2022
    Mind Matters Network, with the support of Malaysia Mental Health Association […]
  • IJN addresses medication non-adherence
    August 16, 2022
    The National Heart Institute or Institut Jantung Negara (IJN) has embarked on […]
  • Pharmaniaga misrepresented Sinovac-Pfizer combo, says MoH
    April 28, 2022
    Pharmaniaga Bhd’s claim of lower heterologous boosting effectiveness for […]
  • Addressing the gaps
    November 29, 2021
    Dr Koh Kar Chai President, Malaysian Medical Association WHILE THE Covid-19 […]

Connect

Office

Revon Media Sdn Bhd
A-5-1, Block A, Parklane Commercial Hub,
Jalan SS 7/26, SS7, 47301 Petaling Jaya,
Selangor Darul Ehsan, Malaysia.

Contact

Tel: +603 7886 6091
Fax: +6 03 3358 0303

Copyright © 2021 Revon Media Sdn Bhd. A publication of Revon Media Sdn Bhd. About Us | Contact Us | Privacy Policy | Terms of use

No Result
View All Result
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us

© 2021 Revon Media Sdn Bhd. A publication of Revon Media Sdn Bhd

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist